Oncological Emergencies

Содержание

Слайд 2

What is Oncologic Emergency? A clinical condition resulting from a metabolic,

What is Oncologic Emergency?
A clinical condition resulting from a metabolic, neurologic,

cardiovascular, hematologic, and/or infectious change caused by cancer or its treatment that requires immediate intervention to prevent loss of life or quality of life.
Слайд 3

Слайд 4

Слайд 5

METABOLIC

METABOLIC

Слайд 6

Hypercalcemia of Malignancy. Major Mechanisms: Local osteolytic hypercalcemia Osteoclastic bone resorbing

Hypercalcemia of Malignancy. Major Mechanisms:

Local osteolytic hypercalcemia
Osteoclastic bone resorbing cytokines
In Extensive bone

metastases - 20%
2) Humoral hypercalcemia of malignancy
Parathyroid hormone related peptide (PTHrP) secreted systemically - 80%
Слайд 7

Слайд 8

Symptoms GI : Nausea, vomiting, Anorexia,Constipation Renal Polyuria due to interference

Symptoms

GI :
Nausea, vomiting, Anorexia,Constipation
Renal
Polyuria due to interference with ADH- Diabetes

insipidus-like syndrome, Polydipsia
Neurologic
Lethargy and fatigue ,Cognitive and behavioural changes ,Altered mental status to coma
Muscle weakness
Слайд 9

Lab Total calcium & albumin or ionized calcium Medical emergency above

Lab

Total calcium & albumin or ionized calcium
Medical emergency above 10.5 mg/dL
Phosphorus
Creatinine,

urea
Electrolytes
50% are hypokalemic
PTH level
If elevated may be primary hyperparathyroidism (or rarely ectopic PTH production)
Слайд 10

Слайд 11

Слайд 12

Слайд 13

Cиндром неадекватной секреции антидиуретического гормона (SIADH)

Cиндром неадекватной секреции антидиуретического гормона (SIADH)

Слайд 14

Слайд 15

Osmotic Demyelination Syndrome Recall that during chronic hyponatremia, osmolytes are shifted

Osmotic Demyelination Syndrome

Recall that during chronic hyponatremia, osmolytes are shifted out

of brain cells to avoid shift of water into cells and brain edema
With rapid correction of [Na], brain cells not able to reaccumulate these osmolytes quickly enough resulting in water shift out of cells hence cell shrinkage and concentrated ion damage1
Слайд 16

Слайд 17

Слайд 18

Acute Tumor Lysis Syndrome Usually starts 6-72 h from initiation of

Acute Tumor Lysis Syndrome

Usually starts 6-72 h from initiation of chemo

or radiotherapy
Due to rapid release of cell contents into blood stream
Most common tumor cause:
Leukemias
Lymphomas
Small cell ca
Слайд 19

Etiologic Factors Large Tumor burden High growth fraction High pre treatment

Etiologic Factors

Large Tumor burden
High growth fraction
High pre treatment serum LDH

or Uric Acid
Preexisting renal insufficiency
Слайд 20

Слайд 21

Слайд 22

Treatment Best treatment – prevention Hydration – 3L\24h, better started 24-48

Treatment

Best treatment – prevention
Hydration – 3L\24h, better started 24-48 h

before treatment initiation
Stop nephrotoxic drugs
Monitoring of electrolyte levels
Urine alkalinization Ph >7.5
Allopurinol
Слайд 23

Stop the chemotherapy Aggressive IV hydration / diuresis CaCl2, NaHCO3, glucose

Stop the chemotherapy
Aggressive IV hydration / diuresis
CaCl2, NaHCO3, glucose / insulin,

kayexalate for hyperkalemia
Rasburicase
Emergency hemodialysis
If K > 6, urate > 10, creat. > 10, or unable to tolerate diuresis
Слайд 24

Слайд 25

Слайд 26

Слайд 27

STRUCTURAL: Neurologic emergencies

STRUCTURAL:

Neurologic emergencies

Слайд 28

Spinal Cord Compression

Spinal Cord Compression

Слайд 29

What is malignant spinal cord compression? Occurs when cancer cells grow

What is malignant spinal cord compression?

Occurs when cancer cells grow in/near

to spine and press on the spinal cord & nerves
Results in swelling & reduction in the blood supply to the spinal cord & nerve roots
The symptoms are caused by the increasing pressure (compression) on the spinal cord & nerves
Слайд 30

Most commonly seen in Breast Lung Prostate Lymphoma Myeloma About 10%

Most commonly seen in
Breast
Lung
Prostate
Lymphoma
Myeloma
About 10% of patients with cancer overall

What types

of cancer cause it?
Слайд 31

Method of spread 85%From vertebral body or pedicle 10% Through intervertebral

Method of spread

85%From vertebral body or pedicle
10% Through intervertebral foramina (from

paravertebral nodes or mass)
4% Intramedullary spread
1%(Low) Direct spread to epidural space (Batson’s plexus)
Слайд 32

Location Thoracic spine 60-70% Lumbosacral spine 20-30% Cervical and sacral spine less then 10% each

Location

Thoracic spine 60-70%
Lumbosacral spine 20-30%
Cervical and sacral spine less then 10%

each
Слайд 33

Слайд 34

First Symptoms Pain 95% Weakness 5% Ataxia 1% Sensory loss 1% RED FLAGS…..

First Symptoms
Pain 95%
Weakness 5%
Ataxia 1%
Sensory loss 1%

RED FLAGS…..

Слайд 35

First Red Flag: Pain Usually first and most common symptom (80-90%)

First Red Flag: Pain

Usually first and most common symptom
(80-90%)
Usually precedes

other neurologic symptoms by weeks to month
Severe local back pain
Aggravated by lying down
Pain may feel like a 'band' around the chest or abdomen (radicular)
Слайд 36

Second Red Flag: Motor Weakness: 60-85% At or above conus medularis

Second Red Flag: Motor

Weakness: 60-85%
At or above conus medularis
Extensors of the

upper extremities
Above the thoracic spine
Weakness from corticospinal dysfunction
Affects flexors in the lower extremities
Patients may be hyper reflexic below the lesion and have extensor plantars
Слайд 37

Third Red Flag: Bladder & Bowel Function Loss is late finding

Third Red Flag: Bladder & Bowel Function

Loss is late finding
Problems passing

urine
may include difficulty controlling bladder function
passing very little urine
or passing none at all
Constipation or problems controlling bowels
Autonomic neuropathy presents usually as urinary retention
Rarely sole finding
Слайд 38

Investigations & information needed prior to therapy MRI scan of the

Investigations & information needed prior to therapy

MRI scan of the whole

spine
Can get compression at multiple levels
Knowledge of cancer type & stage
Knowledge of patient fitness
Current neurological function
Have they lost power in their legs?
Can they walk?
Do they need a catheter?
Do they have pain?
Слайд 39

Treatment options include: Immobilisation Steroids & gastric protection Analgesia Surgery –

Treatment options include:

Immobilisation
Steroids & gastric protection
Analgesia
Surgery – decompression &

stabilisation of the spine
Radiotherapy
Chemotherapy e.g. lymphoma
Hormonal manipulation e.g. prostate Ca
Слайд 40

Indications for Surgery • Unknown primary tumour • Relapse post RT

Indications for Surgery

• Unknown primary tumour
• Relapse post RT
• Progression while

on RT
• Intractable pain
Instability of spine
• Patients with a single level of cord compression who have not been totally paraplegic for longer than 48 hours
Prognosis >3 months
Слайд 41

Surgery

Surgery

Слайд 42

Слайд 43

Слайд 44

Слайд 45

Improvement in surgery + RT Days remained ambulatory (126 vs. 35)

Improvement in surgery + RT
Days remained ambulatory (126 vs. 35)
Percent that

regained ambulation after therapy (56% vs. 19%)
Days remained continent (142 vs. 12)
Less steroid dose, less narcotics
Trend to increase survival

Patchell, R, Tibbs, PA, Regine, WF, et al. A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis (abstract). proc Am Soc Clin Oncol 2003; 22:1.

RCT comparing surgery followed by RT vs. RT alone

Слайд 46

Radiation Therapy

Radiation Therapy

Слайд 47

Слайд 48

Prognosis Median survival with MSCC is 6 months Ambulatory patients with

Prognosis

Median survival with MSCC is 6 months
Ambulatory patients with radiosensitive tumours

have the best prognosis
Likely to remain mobile

MSCC is a poor prognostic indicator in cancer patients
Need better detection rates

Слайд 49

Superior Vena Cava Syndrome

Superior Vena Cava Syndrome

Слайд 50

Слайд 51

Superior Vena Cava Syndrome

Superior Vena Cava Syndrome

Слайд 52

Superior Vena Cava Syndrome

Superior Vena Cava Syndrome

Слайд 53

Слайд 54

Superior Vena Cava Syndrome

Superior Vena Cava Syndrome

Слайд 55

Слайд 56

Слайд 57

In rare cases can be disease presentation No time for pathology

In rare cases can be disease presentation
No time for pathology
Urgent

treatment without tissue diagnosis
Median survival – 6 month
2 year survivale – 15%

Superior Vena Cava Syndrome

Слайд 58

Exeption: Treatment Sensitive Tumors NHLs, germ cells, and limited-stage small cell

Exeption: Treatment Sensitive Tumors

NHLs, germ cells, and limited-stage small cell lung

cancers usually respond to chemotherapy and or radiation
Can achieve long term remission with tumor specific directed therapy
Symptomatic improvement usually takes 1-2 weeks after start of therapy
Слайд 59

Superior Vena Cava Syndrome

Superior Vena Cava Syndrome

Слайд 60

Superior Vena Cava Syndrome

Superior Vena Cava Syndrome

Слайд 61

Superior Vena Cava Syndrome

Superior Vena Cava Syndrome

Слайд 62

Treatment Options Radiation therapy Chemotherapy Intraluminal Stent +supportive care

Treatment Options

Radiation therapy
Chemotherapy
Intraluminal Stent
+supportive care

Слайд 63

Supportive Care: Rest Head elevation Oxygen Diuretics Anticoagulation Steroids Avoid high

Supportive Care:

Rest
Head elevation
Oxygen
Diuretics
Anticoagulation
Steroids
Avoid high volume fluid infusion through upper

extremities
Слайд 64

Intraluminal Stents Endovascular placement under fluoroscopy Patients who have recurrent disease

Intraluminal Stents

Endovascular placement under fluoroscopy
Patients who have recurrent disease in previously

irradiated fields
Tumors refractory chemotherapy
Patient too ill to tolerate radiation or chemotherapy
Слайд 65

Слайд 66

Endovascular stenting and angioplasty Superior vena cava syndrome

Endovascular stenting and angioplasty

Superior vena cava syndrome

Слайд 67

Слайд 68

Слайд 69

Слайд 70

Most Common type of CNS malignancy 20-40% of cancer patients will

Most Common type of CNS malignancy
20-40% of cancer patients will develop

brain mets
Most common types: Breast, Lung, Melanoma, Colorectal Ca
Highest risk for bleeding
RCC
Melanoma
Choriocarcinoma
Papillary thyroid
Lung Cancer

Brain Metastasis

Слайд 71

Recursive Partitioning Analysis - RPA גרורות מוחיות Brain Metastasis

Recursive Partitioning Analysis - RPA

גרורות מוחיות

Brain Metastasis

Слайд 72

גרורות מוחיות Brain Metastasis

גרורות מוחיות

Brain Metastasis

Слайд 73

Diagnosis: CT with and without contrast MRI – modality of choice

Diagnosis:
CT with and without contrast
MRI – modality of choice for small

lesions including leptomeningial spread
If no previous history of malignancy - consider total body imaging

גרורות מוחיות

Brain Metastasis

Слайд 74

גרורות מוחיות Brain Metastasis

גרורות מוחיות

Brain Metastasis

Слайд 75

גרורות מוחיות Brain Metastasis

גרורות מוחיות

Brain Metastasis

Слайд 76

גרורות מוחיות Brain Metastasis

גרורות מוחיות

Brain Metastasis

Слайд 77

Treatment: Steroids – Dexamethasone 16mg*2 Anticonvulsant Surgery? Radiation therapy גרורות מוחיות Brain Metastasis

Treatment:
Steroids – Dexamethasone 16mg*2
Anticonvulsant
Surgery?
Radiation therapy

גרורות מוחיות

Brain Metastasis

Слайд 78

Radiation therapy WBRT=Whole Brain RT SRS=Stereotactic Radio Surgery גרורות מוחיות Brain Metastasis

Radiation therapy
WBRT=Whole Brain RT
SRS=Stereotactic Radio Surgery

גרורות מוחיות

Brain Metastasis

Слайд 79

גרורות מוחיות German Helmet Brain Metastasis

גרורות מוחיות

German
Helmet

Brain Metastasis

Слайд 80

גרורות מוחיות Brain Metastasis

גרורות מוחיות

Brain Metastasis

Слайд 81

גרורות מוחיות Brain Metastasis

גרורות מוחיות

Brain Metastasis

Слайд 82

SRS

SRS

Слайд 83

גרורות מוחיות Brain Metastasis

גרורות מוחיות

Brain Metastasis